These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21179868)

  • 1. [Intensive efforts for future antidiabetic agents].
    Berne C
    Lakartidningen; 2010 Nov 10-16; 107(45):2815-9. PubMed ID: 21179868
    [No Abstract]   [Full Text] [Related]  

  • 2. [New therapies for type 2 diabetes mellitus].
    Puig-Domingo M; Pellitero S
    Med Clin (Barc); 2015 Jun; 144(12):560-5. PubMed ID: 25194974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New targets in type 2 diabetes therapy].
    Hinneburg I
    Med Monatsschr Pharm; 2010 Aug; 33(8):280-4. PubMed ID: 21189647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin-based therapies for type 2 diabetes mellitus: New therapeutic mechanisms.
    Kennedy L
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S2-3. PubMed ID: 19952299
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs for type 2 diabetes.
    Treat Guidel Med Lett; 2011 Aug; 9(108):47-54. PubMed ID: 21778966
    [No Abstract]   [Full Text] [Related]  

  • 6. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Potential new antidiabetics for the next decade].
    Svacina S
    Vnitr Lek; 2009 Apr; 55(4):429-33. PubMed ID: 19449764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Cell signalling and insulin secretagogues: A path for improved diabetes therapy.
    Seino S; Sugawara K; Yokoi N; Takahashi H
    Diabetes Obes Metab; 2017 Sep; 19 Suppl 1():22-29. PubMed ID: 28880474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin analog initiation and titration.
    Hinnen D
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():12-6. PubMed ID: 19402255
    [No Abstract]   [Full Text] [Related]  

  • 11. Trial watch: SGLT2 inhibitor shows promise in type 2 diabetes.
    Nat Rev Drug Discov; 2010 Mar; 9(3):182. PubMed ID: 20190779
    [No Abstract]   [Full Text] [Related]  

  • 12. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early use of insulin for beta cell preservation.
    Kumar A
    J Assoc Physicians India; 2007 Jul; 55 Suppl():26-8. PubMed ID: 17927008
    [No Abstract]   [Full Text] [Related]  

  • 14. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
    DeFronzo RA
    Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic implications of incretin-based therapies.
    Briggs GC
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():18-26. PubMed ID: 18405145
    [No Abstract]   [Full Text] [Related]  

  • 17. Insulin therapy for type 2 diabetes.
    Pergallo-Dittko V
    Diabetes Self Manag; 2003; 20(5):17, 21, 23-4. PubMed ID: 14679948
    [No Abstract]   [Full Text] [Related]  

  • 18. [Oral antidiabetic agents for the general practitioner].
    Siegmund T
    MMW Fortschr Med; 2009 Apr; 151(14):86, 88-91; quiz 92. PubMed ID: 19504847
    [No Abstract]   [Full Text] [Related]  

  • 19. Mouse models of type II diabetes mellitus in drug discovery.
    Baribault H
    Methods Mol Biol; 2010; 602():135-55. PubMed ID: 20012397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lantus is superior in BOT (basic oral therapy) to standard mixed insulin].
    Krankenpfl J; 2004; 42(5-6):172. PubMed ID: 15527234
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.